Source:Wall Street Journal - Greater scrutiny from governments and regulators, mounting doctor irritation at hard-charging drug companies and the waning influence doctors have over prescribing are all driving a wedge between companies and the physicians they've long courted.
11.12 AM Dec 18th
one can see that the company stated that company has taken corrective measures as per USFDA warning letter. FOREIGH BRPKERAGE HOUSE NUMURA GIVEN BUY CALL TARGET 180. COMPANY GOT USFA APPROVAL AND ANDA apprvel fr drugs. company expending aggressively this wiull reflect in sales and prfit in next
10.24 AM Dec 9th
READ n DECIDE.. NO RAY of HOPES Soon? "MANIPULATED the data, Misguided FDA" Charges are more Serious & damaging the reputation & Financials of the Co. `Data integrity issues at drug factories attract severe penal action from the regulator as well as government agencies. Many drug companies
7.53 PM Dec 5th
Everyone is requested to read my past message regarding USFDA real working and intention for Indian Drug Mfg. companies. They are money spinner for US Govt and always provide huge huge penalities to Indian Drug companies. By these method they target two bird by one stone, one huge money earning
11.51 AM Dec 5th
of "Patent/Drug Development" Infringements from Varied "Hemispheres" Drug Companies, going Forward, Even as Actual Clarity/response to its "Alleged Clandestine" R/D Centre. by Drug enforecment Authorites has not been communicated to its Investors. with Regulatory/Settlement Activities on Varied Fronts
6.40 PM Nov 24th
Results are good. Also Govt is tightening on other indian drug companies now . But they wont be able to mylan deal. So its good for strides as it will get an upper hand on other indian companies having such a deal. So we may see good buying in this stock
8.42 PM Nov 17th
Follow moneycontrol.comFacebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.